Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in antiphospholipid antibody (Hughes') syndrome [2]

Journal of Rheumatology

Volumn 29, Issue 7, 2002, Pages 1574-1575

  Yoon, Kam Hon ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYCHLOROQUINE;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EYE TOXICITY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOMODULATION; INTERNATIONAL STANDARD UNIT; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; MALE; PROGNOSIS; PROSPECTIVE STUDY;

ANTIPHOSPHOLIPID SYNDROME; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMAN; HYDROXYCHLOROQUINE; MALE; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; HUMANS;

EID: 0035992970     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (18)

1. Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome
2. The management of thrombosis in the antiphospholipid-antibody syndrome
3. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients
4. Outcome of patients with anticardiolipin antibodies: A ten year follow-up of 52 patients
5. Antimalarial agents and lupus
6. Antiaggregant action of chloroquine
7. On the inhibitory effect of chloroquine on blood platelet aggregation
8. Chloroquine inhibits stimulated platelets at the arachidonic acid pathway
9. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice
10. Prevention of postoperative deep vein thrombosis in legs by orally administered hydroxychloroquine sulphate
11. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement
12. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty
13. Modification of transoperative changes in blood fluidity by hydroxychloroquine: A possible explanation for the drug's antithrombotic effect
14. Does hydroxychloroquine protect against clot formation in systemic lupus erythematosus?
15. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE
16. Incidence and predictors of thrombotic events in SLE: Protective role of hydroxychloroquine
17. Hydroxychloroquine (HCQ) treatment in antiphospholipid antibody syndrome (APS): Time course of clinical improvement and antiphospholipid antibody (aPL) titer changes over 4 years
18. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies